Skip to content

Author

A. Iavarone

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

TAZ mediates enhancer reprogramming blocks neuronal differentiation in glioma stem-like cells.

Brain tumors such as glioblastomas contain hierarchically organized, tumor-propagating glioma stem-like cells (GSCs). A non-cytotoxic strategy to limit the growth of these cells involves promoting terminal differentiation and mitotic exit; however, these approaches have remained largely unsuccessful. In this study, we combined in silico, in vitro, and in vivo methods to determine the influence of transcriptional coactivator with PDZ-binding motif (TAZ), an oncogenic transcription coactivator, in regulating cellular hierarchies in GSCs. We found that TAZ inhibits the neuronal lineage pathway in gliomas and GSCs, and that TAZ expression inversely correlates the master transcription factors (TFs) that drive neuronal fate. Overexpression of TAZ in GSCs disrupted neuronal differentiation by restructuring the enhancer landscape and downregulating essential master TFs associated with neurogenesis, such as OLIG2 and ASCL1. These effects were mediated by histone deacetylases 1 HDAC1). Knockdown of TAZ and its paralog YAP caused aberrant neuronal differentiation of GSCs. Thus, directed neuronal fate can be achieved by blocking TAZ/HDAC complexes, uncovering a novel mode of cellular differentiation that can be utilized as a non-cytotoxic therapeutic strategy for malignant gliomas.

A. Audia, M. Mattohti, V. Ravikumar et al. · 0 citations
Review Aug 2026

Exploring the landscape of targetable alterations in patients with glioblastoma.

The therapeutic landscape of targeted therapies in glioblastomas is summarized, spanning major target classes including receptor tyrosine kinases, intracellular signalling proteins, cell-cycle dysregulation and synthetic-lethal vulnerabilities and emerging strategies targeting genome integrity and telomeres, epigenetic modulators, and tumour-neural circuitry are examined.

E. Aquilanti, M. Touat, P. French et al. · 0 citations